Non-sustained ventricular tachycardia usually asymptomatic, although brief palpitations may sometimes be experienced. Symptoms in a patient with known NSVT are most often attributed to underlying cardiac disease rather than the arrhythmia itself.
Defined as a self-terminating event. No specific treatment indicated. Management is directed at any underlying heart condition.
Implantable cardioverter defibrillator (ICD) placement may be used for selected patients who have additional risk factors such as structural heart disease. Patients at risk for sudden cardiac death and who also have discordant contraction of left ventricular function may benefit from cardiac resynchronisation therapy (CRT).
Prognosis dependent on presence or absence of cardiac disease. Left ventricular function in post-MI patients remains the most important prognostic tool for overall mortality and risk for sudden cardiac death.
No increase in mortality demonstrated in those patients without associated cardiac disease.
Non-sustained ventricular tachycardia (NSVT) is an ectopic ventricular rhythm with wide QRS complex (120 milliseconds or greater), rate faster than 100 bpm, lasting for at least 3 beats that spontaneously resolves in less than 30 seconds. It may occur in the absence of any underlying heart disease. However, it is more commonly associated with ischaemic and non-ischaemic heart disease; known genetic disorders such as long QT syndrome, Brugada's syndrome, and arrhythmogenic right ventricular cardiomyopathy; congenital heart disease; metabolic problems, including drug toxicity; or electrolyte imbalance.
History and exam
Key diagnostic factors
- history of CAD
- history of hypertrophic cardiomyopathy
- history of idiopathic dilated cardiomyopathy
- presence of other risk factors
- asymptomatic presentation
Other diagnostic factors
- left ventricular systolic dysfunction
- hypertrophic cardiomyopathy
- idiopathic dilated cardiomyopathy
- long QT syndrome
- Brugada's syndrome
- electrolyte imbalance
- drug toxicity
- Chagas' disease and other cardiomyopathies
- catecholaminergic polymorphic VT
- family history of sudden death
- mental or physical stress
1st investigations to order
- electrolyte panel
Investigations to consider
- 24-hour ambulatory ECG monitoring
- cardiac catheterisation
- cardiac MRI with gadolinium
- electrophysiological testing
- stress testing
- genetic screening
no cardiac comorbidity: asymptomatic
no cardiac comorbidity: symptomatic
idiopathic dilated or hypertrophic cardiomyopathy
Fred Kusumoto, MD
Professor of Medicine
Mayo Medical School
Division of Cardiovascular Diseases
Department of Medicine
Mayo Clinic Florida
FK declares that he has no competing interests.
Professor Kusumoto would like to gratefully acknowledge Dr Ronald R. Butendieck Jr, a previous contributor to this topic. RRB declares that he has no competing interests.
Sarabjeet Singh, MD
Adult Cardiovascular Fellowship
Department of Cardiology
Chicago Medical School (CMS) and affiliated hospitals
SS declares that he has no competing interests.
Vias Markides, MB(Hons), BS(Hons), MD, FRCP
Consultant Cardiologist and Chair
Royal Brompton & Harefield NHS Trust
Hon. Senior Lecturer
VM declares that he has no competing interests.
- SVT with aberrant conduction
- Electrical artifact
- 2022 AHA/ACC/HFSA guideline for the management of heart failure
- 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
Heart attack: what is it?
What you can do to prevent another heart attackMore Patient leaflets
- Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer